Nuzenio

Cadrenal Therapeutics

Cadrenal Therapeutics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 9 latest news signals 6 publisher sources 100/100 entity strength

Latest news

Cadrenal Therapeutics (CVKD): PNC discloses 8.13% beneficial stake for client - Stock TitanStock Titan · Fri, 07 Aug 2026 17:04:02 GMTCVKD | Cadrenal Therapeutics, Inc. Common Executive Compensation - Quiver QuantitativeQuiver Quantitative · Thu, 06 Aug 2026 00:09:18 GMTCadrenal Therapeutics (CVKD) Slips 2.49% to $1.96 as Shares Test Range-Bound Support - Zigzag Correction - dars.gov.etdars.gov.et · Tue, 04 Aug 2026 02:47:41 GMTCadrenal Therapeutics, Inc. SEC Filing (Aug 3, 2026) - Stock TitanStock Titan · Mon, 03 Aug 2026 21:14:31 GMTCadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation - finance.yahoo.comfinance.yahoo.com · Mon, 03 Aug 2026 12:30:00 GMTCAD-1005 Phase 2 Data Show >25% Absolute Reduction in Thrombotic Events - Stock TitanStock Titan · Mon, 03 Aug 2026 12:30:00 GMTCadrenal Therapeutics announces annual shareholder meeting - BitgetBitget · Mon, 03 Aug 2026 07:00:00 GMTCadrenal Therapeutics Inc (CVKD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKeyTradingKey · Mon, 27 Jul 2026 22:28:33 GMT

Timeline

Fri, 07 Aug 2026 17:04:02 GMTCadrenal Therapeutics (CVKD): PNC discloses 8.13% beneficial stake for client - Stock Titan
Thu, 06 Aug 2026 00:09:18 GMTCVKD | Cadrenal Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
Tue, 04 Aug 2026 02:47:41 GMTCadrenal Therapeutics (CVKD) Slips 2.49% to $1.96 as Shares Test Range-Bound Support - Zigzag Correction - dars.gov.et
Mon, 03 Aug 2026 21:14:31 GMTCadrenal Therapeutics, Inc. SEC Filing (Aug 3, 2026) - Stock Titan
Mon, 03 Aug 2026 12:30:00 GMTCadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation - finance.yahoo.com
Mon, 03 Aug 2026 12:30:00 GMTCAD-1005 Phase 2 Data Show >25% Absolute Reduction in Thrombotic Events - Stock Titan

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Cadrenal Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.